Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Future Trajectory | Explore analysts' optimistic outlook, with price targets ranging from $83 to $95, as Edwards navigates challenges to achieve projected double-digit growth |
Market Positioning | Delve into Edwards' competitive edge in cardiac devices, balancing high P/E ratio with innovation and stability in a fiercely contested market |
TMTT Breakthrough | Rapid expansion in Transcatheter Mitral and Tricuspid Therapies segment emerges as a key growth driver, diversifying revenue streams |
TAVR Dominance | Edwards Lifesciences' strong TAVR growth and potential NCD reopening signal promising future for its flagship product line, driving market leadership |
Metrics to compare | EW | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEWPeersSector | |
|---|---|---|---|---|
P/E Ratio | 34.0x | 22.2x | −0.5x | |
PEG Ratio | −0.51 | 0.45 | 0.00 | |
Price / Book | 4.5x | 3.1x | 2.6x | |
Price / LTM Sales | 7.8x | 2.5x | 3.3x | |
Upside (Analyst Target) | 25.1% | 50.3% | 45.6% | |
Fair Value Upside | Unlock | 21.2% | 5.8% | Unlock |